IceCure Medical Ltd. has announced findings from an independent study evaluating the efficacy and safety of its ProSense® cryoablation technology in treating abdominal wall endometriosis (AWE). The study, conducted at Nîmes University Hospital in France and published in the Journal of Personalized Medicine, involved 14 patients with 23 AWE lesions. Results demonstrated significant pain relief, with median pain scores declining from 8/10 to 0/10 at a three-month follow-up. The procedure was shown to have high efficacy, with MRI confirming complete coverage of the ablation zone and no reported complications. The study supports ProSense® as a viable minimally invasive treatment option for AWE, with potential implications for its commercial application in multiple gynecological indications.